Vascular Ehlers-Danlos Syndrome (VEDS) is a life-threatening genetic connective tissue condition. Early diagnosis can save lives.
Our mission is to save lives and improve the quality of life of individuals with Vascular Ehlers-Danlos Syndrome (VEDS).
By pursuing the most innovative research, educating the medical community, general public and affected individuals, and providing support to patients, families, and caregivers, we can charge forward and improve the outcomes for those living with VEDS.
Euismod magna, at iaculis purus nulla eu nunc uisque volutpat lectus eu posuere blandit. Nunc non nulla consectetur.ss
Euismod magna, at iaculis purus nulla eu nunc uisque volutpat lectus eu posuere blandit. Nunc non nulla consectetur.
Euismod magna, at iaculis purus nulla eu nunc uisque volutpat lectus eu posuere blandit. Nunc non nulla consectetur.
Euismod magna, at iaculis purus nulla eu nunc uisque volutpat lectus eu posuere blandit. Nunc non nulla consectetur.
Euismod magna, at iaculis purus nulla eu nunc uisque volutpat lectus eu posuere blandit. Nunc non nulla consectetur.
Euismod magna, at iaculis purus nulla eu nunc uisque volutpat lectus eu posuere blandit. Nunc non nulla consectetur.
Make Change.
The specialty pharmaceutical company, Aytu BioPharma, announced an update today for the VEDS community on the PREVEnt trial for enzastaurin.
Aytu BioPharma, a pharmaceutical company focused on developing and commercializing novel therapeutics, has announced the initiation of
Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization
Mauris vel elit enim. Integer gravida mauris non augue euismod, laoreet luctus libero hendrerit. Vivamus viverra nulla id purus porta rhoncus.
Morbi viverra malesuada luctus.
Sorry, photo gallery is empty.
Send us a message & we will be in touch
There are many variations of passages of lorem there are many
The VEDS Movement is a division of
The Marfan Foundation. | Privacy Statement